Search SEC
Fundamental Analysis
60 matches · 10756 cached companies
| Company | Fundamental | Momentum | Acceleration | Confidence | Revenue Growth | ROIC | FCF Growth | Op Margin Delta | Share Growth | Dividend Yield | Dividend Years | Payout Ratio | P/E | Signals |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NAGENiagen Bioscience, Inc. | 84.4 | 61.7 | 37 | 91 | +25.17% | +117.43% | n/a | +40.37% | -0.87% | 0% | 0 | n/a | 14.88x | Gross margin expansion, Operating leverage, Net debt reduction, Share count reduction, Strong operating leverage2 warnings |
| CIENCIENA CORP | 76 | 100 | 100 | 100 | +45.34% | +20.74% | +821.46% | +9.7% | +0.69% | 0% | 0 | n/a | 83.36x | Gross margin expansion, Operating leverage, FCF growth, ROIC expansion, Strong operating leverage1 warning |
| HRMYHarmony Biosciences Holdings, Inc. | 77.3 | 44 | 44 | 86 | +31.28% | +43.62% | n/a | +13.95% | +0.39% | 0% | 0 | n/a | 11.73x | Net debt reduction1 warning |
| XBIOXenetic Biosciences, Inc. | 80.9 | 100 | 100 | 78 | +26.16% | n/a | n/a | +383.17% | +48.78% | 0% | 0 | n/a | n/a | Operating leverage, Net debt reduction1 warning |
| PUREPURE BIOSCIENCE, INC. | 68.2 | 100 | 100 | 90 | +15.41% | n/a | n/a | +122.86% | -0.92% | 0% | 0 | n/a | n/a | Operating leverage, Net debt reduction, Share count reduction1 warning |
| ETSTEarth Science Tech, Inc. | 78.1 | n/a | n/a | 73 | +15.65% | n/a | n/a | n/a | -4.25% | 0% | 0 | n/a | 8.59x | Gross margin expansion, Net debt reduction, Share count reduction2 warnings |
| KEQUKEWAUNEE SCIENTIFIC CORP /DE/ | 61.7 | 45.4 | 40.3 | 90 | +31.8% | +12.52% | n/a | n/a | -2.47% | 0% | 0 | n/a | n/a | Gross margin expansion, Net debt reduction, Share count reduction1 warning |
| CSTLCASTLE BIOSCIENCES INC | 59 | 39.3 | 39.6 | 91 | +6.8% | -10.75% | n/a | +36.38% | +6.26% | 0% | 0 | n/a | n/a | Net debt reduction3 warnings |
| BSXBOSTON SCIENTIFIC CORP | 62.1 | 65.3 | 65.3 | 86 | +23.28% | +14.39% | n/a | +10.16% | -1.23% | 0% | 0 | n/a | n/a | Gross margin expansion, Operating leverage, Share count reduction, Strong operating leverage |
| NBIXNEUROCRINE BIOSCIENCES INC | 68.7 | 63.8 | 63.8 | 77 | +41.55% | +22.84% | n/a | -2.23% | +1.66% | 0% | 0 | n/a | 22.63x | Operating leverage, Strong operating leverage3 warnings |
| EWEdwards Lifesciences Corp | 55.2 | n/a | n/a | 83 | +17.25% | +17.94% | n/a | n/a | -1.74% | 0% | 0 | n/a | 39.44x | Net debt reduction, Share count reduction |
| CYCNKorsana Biosciences, Inc. | 55 | 100 | 60 | 82 | +252% | -96.98% | n/a | +443.2% | +66.31% | 0% | 0 | n/a | n/a | Operating leverage, Net debt reduction2 warnings |
| KRSAKorsana Biosciences, Inc. | 55 | 100 | 60 | 82 | +252% | -96.98% | n/a | +443.2% | +66.31% | 0% | 0 | n/a | n/a | Operating leverage, Net debt reduction2 warnings |
| IDXGINTERPACE BIOSCIENCES, INC. | 50.1 | 0 | 0 | 90 | -21.46% | +17.09% | n/a | +11.16% | +0.03% | 0% | 0 | n/a | n/a | Net debt reduction2 warnings |
| IDXGDINTERPACE BIOSCIENCES, INC. | 50.1 | 0 | 0 | 90 | -21.46% | +17.09% | n/a | +11.16% | +0.03% | 0% | 0 | n/a | n/a | Net debt reduction2 warnings |
| EVFMEvofem Biosciences, Inc. | 52.2 | 15.7 | 15.7 | 84 | +1.56% | n/a | n/a | +573.2% | -97.77% | 0% | 0 | n/a | n/a | Gross margin expansion, Share count reduction2 warnings |
| RKDAArcadia Biosciences, Inc. | 52.8 | 0 | 0 | 83 | +0.8% | -210.19% | n/a | +188.79% | +119.04% | 0% | 0 | n/a | n/a | Net debt reduction3 warnings |
| ROIVRoivant Sciences Ltd. | 47.1 | 0 | 0 | 90 | -78.05% | -473.94% | n/a | -15,604.49% | -0.27% | 0% | 0 | n/a | n/a | Share count reduction2 warnings |
| ZIVOZivo Bioscience, Inc. | 66.7 | 100 | 100 | 62 | +191.88% | n/a | n/a | n/a | +28.89% | 0% | 0 | n/a | n/a | Operating leverage, Net debt reduction3 warnings |
| PCRXPacira BioSciences, Inc. | 44.8 | 100 | 100 | 91 | +7% | +2.02% | n/a | -13.04% | -13.38% | 0% | 0 | n/a | 124.62x | Gross margin expansion, Operating leverage, Share count reduction |
| SGHTSight Sciences, Inc. | 48.4 | 100 | 100 | 83 | +5.69% | -225.3% | n/a | +61.93% | +6.27% | 0% | 0 | n/a | n/a | Gross margin expansion, Operating leverage, ROIC expansion1 warning |
| LEXXLexaria Bioscience Corp. | 50.5 | n/a | n/a | 77 | -63.11% | -169.66% | n/a | n/a | +41.65% | 0% | 0 | n/a | n/a | Net debt reduction3 warnings |
| PACBPACIFIC BIOSCIENCES OF CALIFORNIA, INC. | 45.1 | 100 | 100 | 85 | +1.61% | n/a | n/a | +103.46% | +4.65% | 0% | 0 | n/a | n/a | Gross margin expansion, Operating leverage |
| IDYAIDEAYA Biosciences, Inc. | 55.3 | n/a | n/a | 69 | +1,827.57% | n/a | n/a | n/a | n/a | 0% | 0 | n/a | n/a | Net debt reduction |
| CVSICV Sciences, Inc. | 46.4 | 60.4 | 76.3 | 81 | -15.37% | -33.08% | n/a | +46.98% | +11.3% | 0% | 0 | n/a | n/a | Gross margin expansion, Operating leverage, ROIC expansion, Net debt reduction1 warning |
1-25 of 60